This invention relates to novel compounds useful in the treatment of diseases associated with TRPV4 channel receptor. More specifically, this invention relates to certain substituted morpholines and piperidines, according to Formula I ##STR00001## wherein: X is O or CH.sub.2; R1 is optionally substituted C.sub.3-7cycloalkyl, C.sub.3-6cycloalkyl-C.sub.0-6alkyl, optionally substituted C.sub.4-7cycloalkenyl, optionally substituted Het-C.sub.0-7alkyl, optionally substituted Het-C.sub.0-7alkenyl, optionally substituted aryl, optionally substituted heterocycloalkyl, or optionally substituted heteroaryl; R2 is H, branched or optionally substituted C.sub.1-6alkyl, C.sub.3-6cycloalkyl-C.sub.0-6alkyl, Ar--C.sub.0-6alkyl, or Het-C.sub.0-6alkyl; and R3 is optionally substituted heterocycloalkyl, optionally substituted aryl, or optionally substituted heteroaryl;or pharmaceutically acceptable salts, hydrates, solvates and physiologically functional derivatives thereof.